Fate Therapeutics Inc. [NASDAQ: FATE] plunged by -$6.36 during the normal trading session on Friday and reaching a high of $80.70 during the day while it closed the day at $72.16. The company report on March 25, 2021 that Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service.
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, will continue to lead all research and development activities.
“On behalf of our board of directors, shareholders and employees, I want to thank Dan for his tremendous contributions in building Fate Therapeutics over the past decade,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “Dan is a visionary in the field of cell therapy, and it has been a privilege working side-by-side with him to introduce the field of off-the-shelf, iPSC-derived cell therapy to the investor and scientific communities. We wish Dan all the best in his retirement.”.
Fate Therapeutics Inc. stock has also loss -20.08% of its value over the past 7 days. However, FATE stock has declined by -28.41% in the 3 months of the year. Over the past six months meanwhile, it has gained 100.50% and lost -20.64% year-on date.
The market cap for FATE stock reached $7.36 billion, with 87.39 million shares outstanding and 79.71 million shares in the current float. Compared to the average trading volume of 1.04M shares, FATE reached a trading volume of 1577431 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Fate Therapeutics Inc. [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $113.65 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Fate Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 26, 2021. The new note on the price target was released on February 26, 2021, representing the official price target for Fate Therapeutics Inc. stock.
The Average True Range (ATR) for Fate Therapeutics Inc. is set at 8.33, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 234.52. The Price to Book ratio for the last quarter was 16.40, with the Price to Cash per share for the same quarter was set at 4.73.
FATE stock trade performance evaluation
Fate Therapeutics Inc. [FATE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.08. With this latest performance, FATE shares dropped by -16.36% in over the last four-week period, additionally plugging by 100.50% over the last 6 months – not to mention a rise of 209.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 34.02, with the RSI for the last a single of trading hit 28.37, and the three-weeks RSI is set at 37.89 for Fate Therapeutics Inc. [FATE]. The present Moving Average for the last 50 days of trading for this stock 95.37, while it was recorded at 82.35 for the last single week of trading, and 61.41 for the last 200 days.
Fate Therapeutics Inc. [FATE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Fate Therapeutics Inc. [FATE] shares currently have an operating margin of -407.47. Fate Therapeutics Inc.’s Net Margin is presently recorded at -551.59.
Return on Total Capital for FATE is now -34.00, given the latest momentum, and Return on Invested Capital for the company is -46.34. Return on Equity for this stock declined to -55.11, with Return on Assets sitting at -37.50. When it comes to the capital structure of this company, Fate Therapeutics Inc. [FATE] has a Total Debt to Total Equity ratio set at 25.31. Additionally, FATE Total Debt to Total Capital is recorded at 20.20, with Total Debt to Total Assets ending up at 15.63. Long-Term Debt to Equity for the company is recorded at 24.44, with the Long-Term Debt to Total Capital now at 19.50.
Reflecting on the efficiency of the workforce at the company, Fate Therapeutics Inc. [FATE] managed to generate an average of -$621,459 per employee. Receivables Turnover for the company is 11.40 with a Total Asset Turnover recorded at a value of 0.07.Fate Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.80 and a Current Ratio set at 5.80.
Earnings per share (EPS) analysis for Fate Therapeutics Inc. [FATE] stock
With the latest financial reports released by the company, Fate Therapeutics Inc. posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -12.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fate Therapeutics Inc. go to -11.30%.
Fate Therapeutics Inc. [FATE]: Insider Ownership positions
There are presently around $6,258 million, or 95.50% of FATE stock, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 12,629,737, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; FMR LLC, holding 7,604,904 shares of the stock with an approximate value of $548.77 million in FATE stocks shares; and VANGUARD GROUP INC, currently with $489.14 million in FATE stock with ownership of nearly 8.007% of the company’s market capitalization.
Positions in Fate Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 138 institutional holders increased their position in Fate Therapeutics Inc. [NASDAQ:FATE] by around 10,481,949 shares. Additionally, 121 investors decreased positions by around 10,697,790 shares, while 16 investors held positions by with 65,540,742 shares. The mentioned changes placed institutional holdings at 86,720,481 shares, according to the latest SEC report filing. FATE stock had 66 new institutional investments in for a total of 4,250,164 shares, while 28 institutional investors sold positions of 1,258,608 shares during the same period.